KRAS G12 Inhibitor Treatment Options
This video segment examines strategies for managing adverse events associated with adagrasib, comparing its safety profile to other RAS GTPase inhibitors like sotorasib, and discusses key differences, benefits, and risks that may influence treatment selection or consideration of clinical trials.
Video content above is prompted by the following:
- What are some strategies you might consider when treating AEs seen with adagrasib? Which AEs are of greatest concern?
- How do the AEs reported in clinical trial for adagrasib compare with other inhibitors of the RAS GTPase family, like sotorasib and others currently under investigation?
- What are some differences between adagrasib and sotorisib? What are some potential risks or benefits that may lead you to choose one of these over the other?
- When might you consider a clinical trial?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
